about us
our sponsors
We are excited to share our success
| Study Number | Started | Study Name | Indication | Participants |
|---|---|---|---|---|
| GSK ROTA 090 | Coming Soon | XXX liquid formulation of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (XXX) HRV vaccine (Rotarix®, GSK Biologicals) | ROTA Virus | X |
| Promius DFD-06-CD-011 | 05/2017 | An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with XXX(0.025%) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis” | Psoriasis | 5 |
| Verrica Pharmaceuticals VP-102-103 | 05/2017 | A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of XXX Topical Film Forming Solution [0.7% (w/v) XXX in Subjects (2 years and older) with Molluscum Contagiosum | Molluscum | 5 |
| Kimberly Clark 500-17-02 | 05/2017 | Comparison of fecal digestive enzymes in infant aged between 0-1 years old | Skin Assessment | 25 |
| Sanofi Pasteur GRC88 | 10/2016 | Flu vaccine for children 6 to less than 36 months of age. | Vaccine | 95 |
| Novavax RSV-M-301 | 10/2016 | XXX vaccine for mother's in their third trimester of pregnancy. | Vaccine | Currently Enrolling |
| Kimberly Clark 500-16-0002 | 10/2016 | Exploratory study to evaluate the microbial consortia of infants 9 to 12 months experiencing diaper rash when healthy. | Diaper Rash | 25 |
| Roche BP30153 | 10/2016 | Efficacy and safety of xxx in children and adolescents age 5 to 17 years with autism spectrum disorder | Autism | Currently Enrolling |
| Abbott AL19 | 04/2016 | Effect of a supplemented infant formula on infant behavior. | Nutrition | |
| Sanofi Pasteur ADC01 | 04/2016 | Immunogenicity and Safety of a Booster Dose of an Investigational routine vaccine in Adolescents. | Vaccine | 45 |
| Sanofi Pasteur MET56 | 04/2016 | Safety and Immunogenicity of an investigational routine vaccine in Healthy Adolescents. | Vaccine | 18 |
| Pfizer A6531002 | 03/2016 | Evaluate the Efficacy of xxx on Acute Cough in a Pediatric Population | Cough | Currently Enrolling |
| Regeneron R2222-RSV-1332 | 12/2015 | Evaluating efficacy and safety of xxx for the prevention of RSV. | Antibody | 3 |
| Sucampo SAG/0211PFC-1131 | 2015 | Efficacy, Safety, and Pharmacokinetics of xxx in Pediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Constipation | Functional Constipation | |
| Actavis LIN-MD-62 | 2015 | Safety and Efficacy Study of a Range of xxx Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) | Constipation | Currently Enrolling |
| Actavis LIN-MD-63 | 2015 | Safety and Efficacy Study of a Range of xxx Doses Administered Orally to Children, Ages 7 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (i.e., Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation) | Constipation | Currently Enrolling |
| Mead Johnson Project: 3602 | 2015 | To evaluate. fecal microbiota, stool characteristics, growth, formula intake, andserious adverse events will be compared between infants assigned to one of the three study feeding groups through approximately 60 days of age | Nutrition | Currently Enrolling |
| Sanofi Pasteur MET50 | 2014 - 2015 | To evaluate the immunogenicity and safety profile of a single dose of xxx conjugate vaccine compared to that of the licensed vaccine xxx, and when xxx conjugate vaccine is given with xxx and xxx vaccines, in health adolescents 10 to 17 years of age | Vaccine | 120 |
| GSK MMR-162 | 2014 - 2015 | Evaluate the Safety and Immunogenicity of with xxx, xxx and xxx and given on a two-dose schedule to Healthy Children in their 2nd Year of Life | Vaccine | 48 |
| GSK FLUQ-QIV-022 | 2014 | Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine xxx Compared to xxx Influenza vaccine xxx Quadrivalent, Administered Intramuscularly to Children 6 to 35 months of age | Vaccine | 83 |
| Abbott AL-15 | 2014 - 2015 | Investigate the effect of Twice Daily Consumption of an Oral Nutritional Supplement Along with Dietary Counseling for 4 weeks on Improving the Dietary Intake of Macronutrients and Micronutrients among Children with Picky Eating Behaviors aged ≥ 48month to < 73 months | Nutrition | 0 / Sponsor Cancelled |
| MK-5348045-00 | 2014 | The ability of blood from three pediatric age groups (3 to 23 months, 2 to 11 years, and 12 to 17 years) to support thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation ex vivo, as compared to adults will be estimated. The ability of MK-5348 to inhibit TRAP-induced platelet aggregation in pediatric blood ex vivo will be estimated. | Vaccine | 25 |
| B1971033 | 2014 - 2016 | To assess persistence of hSBA response for up to 48months after completion of vaccination with xxx | Vaccine | 18 |
| MEM-MD-69 | 2013 - 2014 | Safety and Tolerability of xxx in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | Autism | 21 |
| MEM-MD-68 | 2013 - 2014 | Safety and Efficacy of xxx in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with xxx | Autism | 10 |
| AL13 | 04/2014 | Healthy Term Infants Fed Milk-Based Formula with a Supplemental Carotenoid | Nutrition | 8 |
| 2013-1069 | 05/2014 | Healthy Term Infants Fad Infant Formula containing DHA xxx | Nutrition | 11 |
| MMR-161 | 09/2014 | A Controlled, Multi-Center, Randomized, Observer-Blind Phase IIIA Study designed to Evaluate the Safety and Immunogenicity of xxx to xxx vaccine when Co-Administered with xxx, xxx and xxx and given on a two-dose schedule to Healthy Children in their 2nd Year of Life” | Vaccine | 120 |
| SAS11538 | 01/2012 | A 6-Month Safety And Benefit Study Of Inhaled xxx Combination Versus Inhaled xxx In The Treatment Of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma” | Asthma | 8 |
| MTA55 | 08/2012 | A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of xxx When Administered to Healthy Subjects at 9 months and Concomitantly with xxx at 15 to 18 Months of Age” | Vaccine | 70 |
| M5I02 | 06/2012 | A Phase 3, Multi-Center, Randomized, Open label Study to Evaluate the Safety and Immunogenicity of xxx and xxx and xxx Vaccine Adsorbed Combined with Inactivated xxx Compared to xxx and xxx Vaccine Adsorbed) + xxx Vaccine xxx as the 5th Dose in Children 4 to 6 Years of Age” | Vaccine | 105 |
| V59_40 | 01/2012 | A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined xxx, xxx Vaccine and xxx in Healthy Adolescents when Administered with xxx. | Vaccine | 23 |
| B1971011 | 05/2011 | A phase 2, randomized, controlled, observer/blinded trial, to assess the safety, tolerability, and immunogenicity of Gardasil (HPV) vaccine and XXX vaccine when administered concomitantly in healthy subjects Age ≥11 To <17 Years | Vaccine | 30 |
| B1971015 | 05/2011 | A Phase 2, Randomized, Controlled, Observer-Blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of xxx Vaccine And xxx Vaccine When Administered Concomitantly In Healthy Subjects Age ≥11 To <17 Years | Vaccine | 66 |
| 419-006 | 05/2011 | A Phase 3 Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of xxx in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly with xxx and xxx | Vaccine | 300 |
| 09.03 | 09/2010 | Effects of 100% Whey, xxx Infant Formula with xxx Ion Signs and Symptoms of Colic | Formula | 0 / Sponsor Cancelled |
| V59_36 | 09/2010 | A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of xxx Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of xxx Administered in the Second Year of Life | Vaccine | 45 |
| 09.04 | 09/2010 | Assessment of growth of infants fed starter formulas with modified protein and symbiotics | Formula | 82 |
| AK66 | 04/2010 | Growth and Tolerance of Healthy Term Infants to a New Infant Formula | Formula | 65 |
| A0221066 | 01/2010 | An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of xxx In Pediatric Overactive Bladder Patients Aged 8-17 Years | UTI | 10 |
| MI-MA213 | 10/2010 | An Observational Prospective Study to Assess Respiratory Cohort 2 Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 week Gestational Age) Outcomes and Risks Tracking Study | RSV | 30 |
| AK54 | 06/2008 | Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants | Formula | 55 |
| AK62 | 04/2008 | Tolerance of Healthy Term Infants Fed Infant Formulas | Formula | 60 |
| A2501060 | 03/2008 | An Open-Label Study to Evaluate the Safety of xxx for up to 1 Year in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome - Follow-Up to a 10 Week, Double-Blind, Placebo-Controlled Trial | Down's Syndrome | 25 |
| A2501059 | 03/2008 | A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy and Safety Of xxx In The Treatment Of The Cognitive Dysfunction Exhibited By ChildrenWith Down Syndrome | Down's Syndrome | 25 |
| AK53 | 08/2007 | Tolerance of Healthy, Term Infants to Infant Formulas | Formula | 65 |
| BLI-AX-001 | 01/2007 | A Double-Blind, Randomized, Parallel, Multicenter Study of xxx Oral Solution in the Treatment of Gastroesophageal Reflux Disease (GERD) Symptoms in Infants Age 30 Days-1 Year | GERD | 50 |
| AK44 | 01/2007 | Pilot Tolerance and Bone Status of Healthy, Term Infants Fed Infant Formulas | Formula | 50 |
| AK39 | 06/2006 | Evaluation of Growth, Safety and Tolerance of a New Infant Formula in Healthy Full-Term Infants | Formula | 65 |
| EFC6820 | 08/2006 | Efficacy and Tolerability of xxx in the treatment of children aged 6-17yrs with ADHD associated insomnia | Insomnia | 15 |
LOCATIONS
3262 Salt Creek Circle Lincoln, NE 68504
3901 Pine Lake Rd, Suite 210 Lincoln, NE 68516
8201 Northwoods Drive Lincoln, NE 68505
1336 West A St, Suite B Lincoln, NE 68522
Phone: 402-465-5600
Fax: 402-327-6074
OFFICE HOURS
9am to 5pm Monday through Friday
CONNECT
Phone: 402-465-5600
Fax: 402-327-6074